DAVIS,
Calif., May 22, 2024 /PRNewswire/ -- Infinant
Health, a privately-held company focused on changing the trajectory
of human health by supporting the development and restoration of
the immune system via the gut microbiome, announces additions
to their advisory team: Dr. Katharine
Knobil and Dr. David
Pompliano. Additionally, Judy Gawlik
Brown has joined the board, representing Manna Tree
Partners, to help prepare the company's expansion into
pharma.
Infinant Health recently announced their submission for ODD
status and are augmenting their team with top-tier experts to
support work underway on their groundbreaking product
Bifidobacterium longum subspecies infantis strain,
INF108, aimed at averting necrotizing enterocolitis (NEC) in
premature infants.
"It is with great pleasure that I announce the addition of three
distinguished individuals to our team at Infinant Health. The
extensive expertise they bring in human clinical trials, coupled
with their profound pharmaceutical knowledge, fortifies our resolve
as we embark on the next pivotal phase of our company's evolution,"
stated CEO Mike Johnson. He
continued, "This strategic move underscores our commitment to
pioneering advancements in the microbiome space and our dedication
to excellence in therapeutic product development."
Katharine Knobil, MD
Dr. Knobil has been
appointed as an Advisor to the Infinant Health Board,
bringing more than 25 years of experience in pharmaceutical
research and product development including global clinical
research, medical affairs and patient safety in large pharma,
biotech, and medtech. Dr. Knobil has strategically led research and
development resulting in regulatory approval and the successful
launch of blockbuster medicines.
Dr. Knobil was the first Chief Medical Officer at Agilent
Technologies, the Chief Medical Officer and Head of Research and
Development at Kaleido Biosciences, and Chief Medical Officer at
GlaxoSmithKline. At GSK, she directed the development of
multiple new chemical entities and product line extensions,
including Flolan for Primary Pulmonary Hypertension and Advair for
COPD. She held roles both domestically and in expat
assignments in London and
Shanghai, where she established
the GSK clinical development organization in China. During her career, Kate led the
development and delivery of presentations at regulatory agencies
worldwide, including multiple FDA Advisory Committees. Dr. Knobil
currently serves on the boards of Pliant Therapeutics, Inc., Marker
Therapeutics, Inc., and Nimbus Therapeutics, LLC.
Dr. Knobil earned a BA in Biology from Cornell University, her Doctor of Medicine degree
from The University of Texas
Southwestern Medical School, completed her internal medicine
residency at the University of Michigan
Medical School, and completed her fellowship in pulmonary and
critical care medicine at Johns Hopkins
University School of Medicine.
David Pompliano,
PhD
Dr. Pompliano has been appointed as an Advisor to
the Infinant Health Board, offering his expertise in the
pharmaceutical space as the company progresses along the
pharmaceutical development path. Dr. Pompliano is a drug
discovery scientist, entrepreneur and executive with >30 years
of experience in the biopharmaceutical industry. Working with
venture-capitalists and academicians, he creates scientifically
precocious, game-changing new commercial enterprises based on
exciting discoveries in academic science.
Dr. Pompliano co-founded, and served as CSO, CIO or CEO of,
Odyssey Therapeutics, Daros, Lodo Therapeutics (acquired by
Zymergen) and Revolution Medicines (RVMD), and helped raise over
$400m in Series A financing. He is
currently co-founder and CEO of Donum Therapeutics. Earlier, as a
senior executive at GlaxoSmithKline and Merck, he led drug
discovery teams that produced pre-clinical credentials for >30
development candidates and five registered anti-infective
(Recarbrio, Altabax) and oncology (Tykerb, Votrient, Promacta)
drugs. As Owner of Sanderling Consulting LLC, he assists investors,
companies, and philanthropies in setting drug discovery strategy,
in executing the operations of preclinical discovery and
development, and in evaluating pharmaceutical assets.
Dr. Pompliano earned the BS and PhD degrees in Chemistry from
the University of Virginia and from
Stanford University, respectively, and
conducted research in enzymology and molecular biology as a
National Institutes of Health Postdoctoral Fellow in Jeremy Knowles' laboratory at Harvard University. He has published more than 50
peer-reviewed papers in the areas of infectious diseases, cancer
drug discovery, and mechanistic enzymology.
Judy Gawlik Brown,
MBA
Judy Gawlik Brown has
agreed to be a Member of the Board of Directors for Infinant
Health, representing Manna Tree Partners. She brings a wealth of
knowledge from her experience in the pharmaceutical and consumer
healthcare industries.
Ms. Brown held various executive roles at global biotechnology
leader Amgen, most recently as SVP of corporate affairs,
responsible for strategic communications, patient advocacy, ESG
strategies, and implementation. Prior to that role, she served as
SVP global business solutions and finance, responsible for the
global business solutions, global internal audit, tax, and treasury
organizations.
Before joining Amgen, Ms. Brown served as EVP of business
operations and CFO at Perrigo Company, where she oversaw all
financial operations as well as IT, government affairs, corporate
communications, shared services, M&A and strategy for over a
decade. During her tenure, she was regularly recognized as a
leading finance executive by Institutional Investor, the
Wall Street Journal and IR Magazine.
Ms. Brown is a Certified Public Accountant and received her
MBA from the University of Chicago and
a BS in accountancy from the University of
Illinois at Urbana-Champaign. She is a board director of
Belden Corporation (NYSE: BDC) where she is a member of the Audit
Committee and Chair of the Finance Committee.
ABOUT INFINANT HEALTH, INC
Infinant Health, Inc
("Infinant Health"), previously known as Evolve Biosystems, is a
privately held company committed to changing the trajectory of
human health by supporting the development of the immune system via
the gut microbiome. Investors in the company include the Bill and
Melinda Gates Foundation, Johnson & Johnson, Cargill, and other
leading institutions. Learn more about Infinant Health
at www.infinanthealth.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/infinant-health-appoints-new-team-members-to-assist-with-drug-development-302151985.html
SOURCE Infinant Health